-
2023-506854-19-00
1
2022-05-19
Solid Tumors
-
2023-507795-51-00
5
2022-05-17
atherosclerotic heart and blood vessel disease (the narrowing of arter
-
2023-507131-38-00
5
2022-05-16
Neovascular Age-Related Macular Degeneration (nAMD)
-
2023-504363-17-00
7
2022-05-13
Advanced MTAP-null solid tumors
-
2023-507069-25-00
4
2022-04-29
Amyloid Light Chain Amyloidosis
-
2024-516914-39-00
5
2022-04-27
Metastatic or unresectable melanoma
-
2024-517528-20-00
4
2022-04-19
Unresectable or metastatic conventional chondrosarcoma
-
2023-506359-68-00
5
2022-04-08
Active Proliferative Lupus Nephritis
-
2023-503517-30-00
5
2022-04-01
Extensive-stage small-cell lung cancer
-
2023-504884-17-00
5
2022-02-04
Proteinuria
-
2023-509631-37-00
5
2022-01-18
"Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Bre
-
2024-515902-15-00
4
2022-01-18
Male and female adult patients with locally advanced or metastatic lar
-
2023-505210-18-00
5
2021-12-17
Early stage HER2-positive breast cancer (T stage >= T3, lymph node pos
-
2024-511535-97-00
10
2021-12-16
sickle cell disease (SCD)
-
2023-509170-33-00
5
2021-11-23
Classic Congenital Adrenal Hyperplasia (CAH)
-
2023-505807-21-00
5
2021-11-16
Relapsed/refractory follicular lymphoma
-
2024-517965-18-00
4
2021-11-11
Advanced NSCLC with common EGFR-Mutation
-
2023-506518-33-00
5
2021-11-10
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
-
2023-507130-24-00
5
2021-10-22
Neovascular age-related macular degeneration (nAMD)
-
2023-503441-55-00
4
2021-10-14
Relapsed/Refractory Multiple Myeloma
-
2024-513091-17-00
5
2021-09-29
Progressive myopia
-
2023-508723-12-00
5
2021-09-27
gastroenteropancreatic neuroendocrine tumors
-
2024-510809-28-00
5
2021-09-27
Metastatic Castration-sensitive Prostate Cancer
-
2023-506926-35-00
5
2021-09-24
Atherosclerotic cardiovascular disease, chronic kidney disease and sys